Dicerna gets breakthrough therapy designation for DCR-PHXC to treat primary hyperoxaluria type 1

Dicerna Pharmaceuticals announced that the US Food and Drug Administration (FDA) has granted a breakthrough Therapy Designation (BTD) to DCR-PHXC for the treatment of patients with primary hyperoxaluria type 1 (PH1)